The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer
Official Title: A Phase 2, Multicenter, Open-label, Single Arm Study of Dostarlimab Plus Carboplatin-paclitaxel Followed by Dostarlimab Monotherapy in Japanese Patients With Primary Advanced or Recurrent Endometrial Cancer (RUBY-J)
Study ID: NCT06317311
Brief Summary: The goal of this clinical trial is to understand the effectiveness of dostarlimab and carboplatin-paclitaxel followed by dostarlimab monotherapy in participants with endometrial cancer
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
GSK Investigational Site, Aichi, , Japan
GSK Investigational Site, Chiba, , Japan
GSK Investigational Site, Ehime, , Japan
GSK Investigational Site, Fukuoka, , Japan
GSK Investigational Site, Fukuoka, , Japan
GSK Investigational Site, Gunma, , Japan
GSK Investigational Site, Hokkaido, , Japan
GSK Investigational Site, Hyogo, , Japan
GSK Investigational Site, Ibaraki, , Japan
GSK Investigational Site, Iwate, , Japan
GSK Investigational Site, Kanagawa, , Japan
GSK Investigational Site, Okayama, , Japan
GSK Investigational Site, Osaka, , Japan
GSK Investigational Site, Osaka, , Japan
GSK Investigational Site, Saitama, , Japan
GSK Investigational Site, Shizuoka, , Japan
GSK Investigational Site, Tochigi, , Japan
GSK Investigational Site, Tokyo, , Japan
GSK Investigational Site, Tokyo, , Japan
GSK Investigational Site, Tokyo, , Japan